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Abstract
Background: Urinary tract infections (UTIs) are a major public health 
problem worldwide. In Latin America, most UTIs are treated without 
bacteriological identification. Our aim was to examine resistance rates 
to commonly prescribed antibiotics, focusing on cases from Jalisco, 
Mexico; and additionally to conduct a review of the literature to search 
for resistance patterns in other countries of Latin America.
Methods: Retrospective analysis of urine cultures from ambulatory 
and hospitalized patients taken from Nov 2012-Nov 2013; susceptibi-
lity testing and minimal inhibitory concentration (MIC) was done by 
microdilution methodology. For literature search, we reviewed diffe-
rent data bases and included papers in English and Spanish, published 
from 2007-2014, representative from the Latin America region.
Results: We obtained 1.206 consecutive samples from outpatient 
and inpatient facilities, including adult and pediatric subjects. The 
most frequent isolate in all groups was ESBL-producing E. coli with 
high resistance rates for ampicillin, TMP-SMX, and ciprofloxacin. In 
the literature review we found 15 papers related to resistance rates 
of commonly prescribed antibiotics.
Conclusions: The information summarized in this article supports 
the finding that resistance rates to commonly prescribed antimicrobial 
agents are increasing worldwide. As such, this study challenges the 
rationale behind empiric use of antibiotics, emphasizing the need, 
whenever possible, to perform urine cultures before initiating antimi-
crobial treatment.
High Microbiological Spectrum Resistance Rates in 
Urine Isolates from Jalisco, Mexico. 
A Retrospective Study and Literature Review 
 orIgInal 
Maria G. Zavala-Cerna1, Nicole Macriz-Romero2, Juan F. Santoscoy-Gutierrez2, Leza Naydich1, 
Fernando A. Santoscoy-Tovar3, Jose A. Rueda-Cruz3, Olivia Torres-Bugarin1, 
Dennis Spalla Morris1, Isidro G. Zavala-Trujillo4
1  School of Medicine, Universidad 
Autonoma de Guadalajara PC 45129 
Jal. México.
2  Facultad de Medicina de la Universidad 
Autónoma de Guadalajara PC 45129, 
Jal. México.
3  Microbiology Department, Unidad 
de Patología Clínica, Guadalajara PC 
44650, Jal. México.
4  Infectious Disease Division, Hospital 
Ángel Leaño, Universidad Autónoma 
de Guadalajara, Guadalajara PC 45200, 
Jal. México.
Contact information:
Maria G. Zavala-Cerna.
Research Professor at Immunology 
Department, School of Medicine. 
Address: Universidad Autonoma de 
Guadalajara ,Av. Patria 1201, Lomas del 
Valle Zapopan, Jal. Mexico 45129. 52 333 
6488824 . Ext.33152. 
 g_zavala_78@hotmail.com
Keywords
Antimicrobial resistance; 
E. coli; Extended spectrum 
beta lactamases; Urine culture.
InternatIonal archIves of MedIcIne
Section: Microbiology 
Issn: 1755-7682 J
2015
Vol. 8 No. 148
doi: 10.3823/1747
This article is available at: www.intarchmed.com and www.medbrary.com 2
Background
Urinary tract infections (UTIs) are a major public 
health problem in terms of morbidity and finan-
cial cost, exceeding that of chronic renal failure 
[1]. UTIs have been reported to affect up to 150 
million individuals annually worldwide [1-3] and 
contribute to >30% of health-care facility associa-
ted infections, as annually reported by acute care 
hospitals [4]. UTIs are one of the most common 
bacterial infections occurring in children and the 
most common bacterial infection diagnosed in 
women [2, 5, 6]. Prompt recognition and correct 
antimicrobial management can relieve symptoms 
and prevent more serious sequelae, such as pro-
gressive kidney damage [5, 6]. Most UTIs (85%) 
are caused by Escherichia coli (E. Coli) and Sta-
phylococcus saprophyticus (10%), with Klebsiella 
pneumoniae and the Proteus species accounting 
for the majority of the remaining etiologic agents 
[1]. In up to 95% of UTI cases, treatment is pres-
cribed without bacteriological identification, even 
in the presence of severe symptoms, the choice 
of treatment relies on local epidemiologic data 
coupled with empirical selection of antibiotics ba-
sed upon the patient’s age and gender [2]. Com-
monly, urine samples are sent for microbiological 
evaluation only following treatment failure, or in 
presence of recurrent or relapsing infection [1]. 
Because most UTIs are generally treated empirica-
lly, the selection of antimicrobial agent should be 
determined not only by the most common patho-
gen, but also from consideration of risk factors 
that may alter that pathogen´s typical susceptibility 
profile. One such risk factor is the production of 
extended spectrum beta lactamases [5, 7]. The 
acquisition of such beta lactamases may be related 
to changes in the bacterial genome by mutation 
or acquisition by horizontal transfer of extrachro-
mosomal genetic material [8, 9]. 
Successful invasion of the urinary tract by bacte-
ria depends on bacterial virulence, inoculum size, 
defense mechanisms in the host, and for women, 
hormone effects and changes in the genital mi-
crobiota due to female anatomical characteristics 
[10, 11]. In cases of community-acquired (CA) 
UTIs (defined as those acquired prior to any hos-
pital admission or more than 10 days after any 
hospital discharge) [12] the knowledge of local 
antimicrobial susceptibility profiles of common 
uropathogens is essential for prudent, empiric 
treatment [1]. Treatment of UTIs generally inclu-
des β-lactam antibiotics, fluoroquinolones, nitro-
furantoin or trimethoprim/sulfametoxazole (TMP/
SMX). Treatment varies according to patient age 
and gender, pathogen implicated, course of disea-
se, and the anatomical area of the urinary tract 
involved [3, 13]. While these drugs are successful 
in resolving some UTIs, resistance to commonly 
prescribed antimicrobial agents is a matter of in-
creasing concern. For example, fluoroquinolone 
resistance has been reported in various countries 
[3], and evidence provides an association between 
quinolone resistance and increased rates for pres-
cription in the community [14]. Indeed, in the span 
of a decade (1997-2007), fluoroquinolone use in 
Latin America has dramatically increased, with 
consumption rates having doubled or tripled du-
ring this period in some countries [15, 16]; more 
importantly, a strong trend indicating increased 
resistance can be seen worldwide. Because of this 
emerging resistance problem, empiric treatments 
are likely to become less effective, particularly in 
an outpatient setting where patient follow-up 
may be limited or nonexistent [7]. Thus, given the 
changing spectrum of microorganisms involved 
in the development of UTIs and the emergence 
of acquired microbial agent resistance, there is a 
heightened need for more rigorous patient scree-
ning to guide empiric therapy [2]. Additionally, lo-
cal data regarding pathogen susceptibility profiles 
with respect to antimicrobial agents coupled with 
knowledge of common UTI risk factors in a parti-
cular locale is expected to lead to better tailoring 
and more effective empiric treatment protocols 
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[3]. Our aim was to examine resistance rates of 
urine isolates to commonly prescribed antibiotics, 
focusing on cases in Jalisco, Mexico; additionally 
to conduct a review of the literature to search 
for resistance patterns in other countries of Latin 
America. 
Methods
We conducted a retrospective analysis of data from 
the microbiology laboratory at “Unidad de Patolo-
gía Clínica” (UPC), in Guadalajara, Jalisco, Mexico, 
which is a reference laboratory in Mexico certified 
by the College of American Pathologists in the La-
boratory Accreditation Program since 2000. 
All microbiological reports on bacterial pathogens 
between November 2012 and November 2013 from 
the state of Jalisco were included in this study.
Sample collection
In all cases, urine was collected by either clean catch 
method or bladder catheterization; samples were 
conserved at room temperature for no more than 2 
hours before they were analyzed. Samples analyzed 
contained >25 white blood cells per microliter, and 
resulted in only one pathogenic micro-organism 
with counts of >100,000 colony forming units per 
milliliter. The decision to perform a urine culture was 
made by the attending physicians. 
Microbiological Analyses
Standard techniques were used for culture and 
identification of pathogens [17]. Non-susceptibi-
lity testing and minimal inhibitory concentration 
(MIC) was performed by microdilution methodolo-
gy [MicroScan® panels (Siemens, Sacramento, CA, 
USA)]. Inhibition for each isolate was defined as 
susceptible, intermediate or resistant, according to 
the guidelines of the Clinical and Laboratory Stan-
dards Institute (CLSI) [18]. Antimicrobials tested 
were amikacin, ampicillin, ampicillin/sulbactam, 
amoxicillin/clavulanate (AMOX/CALV), cefotaxi-
me, cefoxitin, ceftazidime, ceftriaxone, cefuroxi-
me, ciprofloxacin, chloramphenicol, ertapenem, 
gentamycin, imipenem, levofloxacin, meropenem, 
piperacillin, piperacillin/tazobactam (PIP/TAZ), te-
tracycline, ticarcilin/clavulanate, tigecyclin, nitrofu-
rantoin, trimetropim/sulfametoxazole (TMP/SMX) 
and tobramycin.
MicroScan panels comprise dehydrated panels for 
microdilution antibiotic susceptibility. Those used 
for ESBL detection which contains combinations of 
ceftazidime or cefotaxime plus β-lactamase inhibi-
tors have received Food and Drug Administration 
approval; and in studies of large numbers of ESBL-
producing isolates, they have appeared to be highly 
reliable.
Screening for ESBL producers
We used the LabPro software which is capable 
of identifying ESBL strains by phenotypic confor-
mation with ceftazidime, ceftazidime/clavulanate, 
cefotaxime and cefotaxime/clavulanate, as recom-
mended by the CLSI [19]. Growth at or above the 
screening antibiotic concentration was suspicious 
of ESBL production and an indication for the or-
ganism to be tested by a phenotypic confirmatory 
test.
The phenotype confirmatory test for ESBL pro-
duction was performed with use of MicroScan 
panels using ceftazidime (0.25-128 μg/mL), cefta-
zidime plus clavulanic acid (0.25/4 - 128/4 μg/mL), 
cefotaxime (0.25-64 μg/mL), or cefotaxime plus 
clavulanic acid (0.25/4 - 64/4 μg/mL), against the 
isolates, phenotypic confirmation of ESBL produ-
cers was considered as ≥3 twofold serial-dilution 
decreases in minimum inhibitory concentration 
(MIC) of either cephalosporin in the presence of 
clavulanic acid compared to its MIC when tested 
alone.
Study groups
Children and adults were assessed separately. Four 
(4) groups were established for this purpose: 1) Out-
patient adults (OA), 2) Inpatient adults (IA), 3) Out-
patient Pediatric (OP) and 4) Inpatient Pediatric (IP).
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Statistics
For descriptive purposes, mean and standard de-
viation calculations were used for nominal variables 
and proportions for categorical variables. GraphPad 
Prism (5th version) software was used for statistical 
analysis and figure design. 
Ethics
The present study was registered and approved by 
the ethics committee of the “Hospital Angel Leaño, 
Universidad Autónoma de Guadalajara” and patient 
data was managed anonymously to protect privacy.
Literature review
We reviewed data from the available medical lite-
rature. A systematic search of papers was perfor-
med from data bases PUBMED, Clinical Key Elsevier, 
and ProQuest. We used the following search terms: 
“Urine culture”, “Uropathogenic E. coli”, “ESBL”, 
“Antimicrobial resistance” and “Latin America”. We 
included all papers that fall into the scope of the 
present review written in English and Spanish, ob-
tained with dates from 2007 through 2014. 
Results
Study population
A total of 1.206 positive consecutive samples were 
analyzed from the following five metropolitan zones 
located in the state of Jalisco, Mexico: 1) Metropo-
litan zone of Guadalajara (Guadalajara, Ixtlahuacan, 
Tlaquepaque, Tonalá, Tlajomulco, and Zapopan), 2) 
Metropolitan zone of Puerto Vallarta (Bahia de Ban-
deras), 3) Metropolitan zone of Tepatitlán (Tepatit-
lán and Arandas), 4) Metropolitan zone of Ocotlán 
(Ocotlán and Poncitlán) and 5) Metropolitan zone 
of Autlán (Autlán de Navarro). 
The proportion of adults (n=1100) was higher 
compared to children < 18 years of age (n=106). 
Among adults, 91.5% of the cases (1,006) corres-
ponded to outpatients (OA), and 8.5% of the cases 
(94) were inpatients (IA). In the pediatric population 
84.9% of the cases (90) were outpatients (OP) and 
15.1% (16) were inpatients (IP). Age and gender 
comparisons from each of the four analysis groups 
are set forth in Table 1. 
Microbiologic spectrum
The most frequent bacterial isolate in this study 
was ESBL-producing E. coli. The overall incidence of 
this pathogen was 68.3% (824/1.206), with simi-
lar proportions amongst the four analysis groups: 
OA (69.5%), IA (72.4%), OP (53.3%) and IP (50%); 
followed by non-producing ESBL E. coli. Table 2 
provides the most frequently found pathogens in 
urine cultures.
Antibiotic resistance
In line with the determination that the most com-
mon bacterial isolate found was ESBL-producing 
E. coli, elevated rates of resistance in this bac-
teria were likewise found in adult outpatients/
inpatients to commonly prescribed drugs like 
ampicilline/sulbactam (100/100%), ceftriaxo-
ne (66.1/72.1%), trimethoprim sulfametoxazole 
(TMP/SMX) (64.8/55.9%) and to ciprofloxacin 
(85.7/92.6%). These elevated resistance rates were 
also found in children, from both inpatients/out-
patients: ampicillin/sulbactam (100/100%), cef-
triaxone (54.2/37.5%), TMP/SMX (72.9/62.5%), 
and ciprofloxacin (60.4/50.0%). With respect to 
non-ESBL E. coli, resistance rates were significant 
Table 1.  Demographic characteristics of the study 
population.
Adults (n= 1100) Pediatric (n= 106)
OA IA OP IP
n (%) 1006 (91.5) 94 (8.5) 90 (84.9) 16 (15.1)
Age 
(mean±SD)
60.4±19.7 62.3±21.3 5.3±4.3 2.2±1.9
Female sex 
(%)
82.7 49.5 86.7 70.6
OA outpatient adults, IA inpatient adults, OP outpatient 
pediatric, IP inpatient pediatric, SD standard deviation.
InternatIonal archIves of MedIcIne
Section: Microbiology 
Issn: 1755-7682 
2015
Vol. 8 No. 148
doi: 10.3823/1747
© Under License of Creative Commons Attribution 3.0 License 5
but not as elevated as those for ESBL-producing E. 
coli, except for a significant proportion of isolates 
that were found to be resistant to ciprofloxacin 
in adults (47.8-47.4%) and, to a lesser extent, 
in children (15.2-25%). Conversely, susceptibility 
rates within E. coli isolates (both ESBL and non-
ESBL producers) were >95% for carbapenems 
and >69% for nitrofurantoin. A complete appre-
ciation of the antimicrobial resistance from ESBL 
E. coli and non-ESBL E. coli is set forth in Figure 
1. More detailed information on ESBL and non-
ESBL E. coli, Klebsiella, Morganella, and Proteus 
bacteria is provided in the Table 4 for adults and 
Table 5 for the pediatric group.
Table 2.  Frequencies of pathogens found in urine 
cultures among different groups.
Adults (n= 1100) Pediatric (n= 106)
OA 
(n=1006)
IA 
(n=94)
OP 
(n= 90)
IP 
(n= 16 )
n (%) n (%)
ESBL E. coli 700(69.5) 68 (72.4) 48 (53.3) 8 (50.0)
Non-ESBL 
E. coli
251 (25.0) 19(20.2) 33 (36.7) 4 (25.0)
Klebsiella 
ozanae
10 (1.0) 2 (2.1) 1 (1.1) 2 (12.4)
Klebsiella 
pneumoniae
15 (1.5) 2 (2.1) 1 (1.1) 0 (0)
Morganella 
morgani
19 (1.9) 2 (2.1) 2 (2.2) 1 (6.3)
Proteus 
mirabilis
11 (1.1) 1 (1.1) 5 (5.6) 1 (6.3)
OA outpatient adults, IA inpatient adults, OP outpatient 
pediatric, IP inpatient pediatric, SD standard deviation.
Figure 1:  Antimicrobial resistance of extended spectrum beta lactamases (ESBL) and non-ESBL E. coli to most 
common prescribing drugs for urinary tract infections treatment. 
Amikacin (AMK), gentamicin (GEN), ampicillin sulbactam (AMP/SUL), ampicillin (AMP), cefuroxime (CEF), ciprofloxacin (CIPRO), levofloxacin (LEVO), 
trimethoprim sulfametoxazole (TMP/SMX) and nitrofurantoin (NITRO).
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Literature review
We found 15 different studies performed in Latin 
America from 2007-2014; in Mexico, data regarding 
the epidemiology of ESBL-producing enterobacte-
riaceae, most specifically, ESBL-producing E. coli, is 
scarce, in both outpatient and inpatient settings. 
After reviewing studies performed in Latin America, 
we confirmed the presence of high resistance rates 
to commonly prescribed antimicrobial agents. Table 
3 summarizes different studies results performed in 
different countries from America with resistance ra-
tes of E. coli isolated from urine cultures. Infections 
comprising resistant E. coli are typically associated 
with increased age of patient, hospitalization, recent 
antibiotic use, chronic medical conditions, surgery, 
and immunosuppression. The high resistance rates 
reported in Mexico, as well as those from other 
studies in this region, demonstrate a need to better 
characterize pathogenic isolates in UTI cases.
Discussion 
There is a recognized significant challenge with an-
timicrobial resistance among important gram-ne-
gative organisms including E. coli worldwide [20]. 
In recent years, extended-spectrum β-lactamases 
(ESBLs) have increased in type and frequency, such 
as enterobacteriaceae and carbapenemases, which 
have resulted in a worldwide dissemination of such 
extended spectrum β-lactamases producing strains 
[21]; production of extended spectrum β-lactamases 
(ESBLs) is currently a matter of increasing global 
concern [5, 22]. Ruppe and Cols identified that the 
occurrence of UTI caused by ESBL E. coli in women 
who were not exposed to antibiotics was linked to 
the relative amount of fecal ESBL E. coli [23].
Results from our study echoes previous reports 
finding the main causative organism of UTIs to be 
E. coli [24]. But perhaps most importantly, we found 
an even higher proportion of E. coli producers of 
ESBL in the isolates examined in here. This finding 
corresponds with previous studies not only in the 
Latin American region [15], but also from the Asia/
Pacific region (where India, China and Thailand re-
ported the highest prevalence rates of ESBL-produ-
cing E. coli: 79.0%, 55.0% and 50.8% respectively 
[25]). In contrast, the results from this study differ 
from those conducted in other parts of the world, 
mainly North America and Europe; for example, in a 
study performed in Scotland on enterobacteriaceae 
isolates, only 7.5% of the isolates were phenotypi-
cally confirmed ESBL producers [26]. Nevertheless, 
Kassakian et al [27] recently reported an increase in 
the prevalence of community-acquired and health-
care-associated infections in the U.S. due to ESBL-
producing bacteria, particularly urinary tract infec-
tions due to ESBL-producing E. coli, with notably 
high resistance rates to ciprofloxacin (95%). Thus, 
further study of ESBL-producing enterobacterieae, 
particularly ESBL-producing E. coli, continues to ap-
pear highly warranted.
The discrepancies encountered in different parts 
of the world may be attributed to antimicrobial 
distribution practices. This especially holds true in 
countries that forego prescriptions altogether and 
permit sales of such drugs over-the-counter. For 
example, the practice in México was to sell antimi-
crobials over-the-counter until 2010, at which time 
physician prescriptions became a requirement. Im-
portantly, some studies have identified international 
travel as a risk factor for the colonization by and in-
fection with resistant E. coli [6, 22, 28]. This finding 
highlights the importance of recognizing resistance 
patterns in different parts of the world, particularly 
in places where tourism attracts many international 
travelers.
ESBL are beta-lactamases that hydrolyze exten-
ded spectrum cephalosporins with an oxyimino 
side chain [6]. Community acquisition of ESBL-
producing E. coli was first reported in Ireland in 
1998, where an ESBL producing nalidixic acid-
resistant uropathogenic E. coli strain was isolated 
from an elderly patient who did not have a recent 
history of hospitalization. Since then, ESBL-produ-
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Table 3. Resistance rates (%) in E. coli isolates from urine cultures in different countries of America since 2007.
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Pediatric  
PUC
4 80 - 40 - - 30 - 17 18 - 3 27 - 19 - - 72 - - 2
MEX 
2007
[32]
Uncomplicated 
UTIs
- 73 - 23 - - - - - - 8 4 28 - - - 66 2 - -
MEX 
2007
[33]
Outpatients 
PUC
2.5 67.2 - 13.9 35.6 - 14.3 - - 3.5 - - 24.7 - - - - 59.2 13.2 - -
MEX 
2009
[34]
U
nc
om
pl
ic
at
ed
 
U
TI
s
Outpatients 0 - 71 39 - - 24 - - 14 10 9 50 _ - - 3 55 - - 1
MEX 
2010
[35]
Inpatients 1 - 83 61 - - 36 - - 16 19 19 71 - - - 7 66 - - 1
O
ut
pa
tie
nt
s 
PU
C
 
non-ESBL - - - - - - - - - - - - 29.7 13.4 27.6 - - 56.5 8.2 - -
MEX 
2012
[36]
ESBL - - - - - - - - - - - - 13.4 6.8 14.1 - - 17.2 7.5 - -
In
pa
tie
nt
s 
PC
U
non-ESBL - - - - - - - - - - - - 43.5 26.4 49.0 - - 71.7 5.6 - -
MEX 
2012
ESBL - - - - - - - - - - - - 72.4 41.4 79.3 - - 96.5 51.7 - -
IC
U
 
PU
C
non-ESBL - - - - - - - - - - - - 66.7 33.3 66.7 - - 66.7 0 - - MEX 
2012ESBL - - - - - - - - - - - - 83.3 83.3 83.3 - - 100 50.0 - -
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Outpatients 
PUC
- - 40 37 21.5 17.7 8.6 - - - - 40.8 - 40.8 14.6 - 54.4 6 - -
MEX 
2013
[37]
CA 
UTIs
0 100 85 - 100 100 48 100 - 100 - 98 - 96 - - - - 0 -
MEX 
2013
[14]
PUC 2.9 90.6 44.4 - - - - - - - - 0 13.9 - 0.9 7.7 - 72.0 21.1 0 -
COL 
2007
[38]
PU
C
Outpatients - - 21.3 - 5.6 - - - 1.1 1.1 - 1.1 22.5 - - 9.4 - 39.2 1.8 - -
COL 
2009
[39]Inpatients - - 31.6 - 8.5 - 5.6 - 2.8 2.8 - 2.8 37.6 - - 13 0.6 44.6 1.7 0 -
ICU - - 43.9 - 12.2 - 9.5 - 2.4 2.4 - 2.4 34.1 - - 26.8 0 46.3 0 0 -
Outpatients - 57.4 - - - 38.3 - - - - - - - - - - - 44.7 - - - BRA 
2014
[40]
Inpatients - 38.9 - - - 16.3 - - - - - - - - - - - 33.2 - - -
ED - - - - - - - - - - - - - - 17.6 - - 27.5 - - -
USA
2013
[41][
CA UTI 1.4 - 29.3 - - - - - 10.8 - 2.5 8.3 46.3 - - - 2.9 58.6 2.5 0 -
GUA
2011
[42]CA UTI 0.9 72 27 - 8 29 9 - - 3 - - 41 - - - - 57 7 - -
ECU
2007
CA UTI 7.5 53.6 - - - 31.8 - 5.6 - - - 19.6 - - - 6.4 29.6 4 0 0
CHI
2009
Complicated and 
uncomplicated UTI
2.3 61.4 - 18.6 - 45.5 - - - 20.5 - - 31.8 - - - - 38.6 7.0 - -
NIC
2010
[43]
Mexico (MEX), Colombia (COL), Guatemala (GUA), Chile (CHI), Nicaragua (NIC), Ecuador (ECU), Brazil (BRA), Positive urine cultures (PUC), urinary tract infection (UTI), trymetroprim 
sulfametoxazole (TMP/SMX) ampicillin sulbactam (AMP/SUL), amoxicillin clavulanate (AMOX/CLAV), piperacilin tazobactam (PIP/TAZ), Emergency department (ED), Centers for 
Disease Control and Prevention (CDC), Intensive care unit (ICU), Extended spectrum beta lactamases (ESBL),  community acquired (CA). 
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Table 4.  Antimicrobial activity against Gram-negative organisms collected 
from urine samples in adults from Jalisco, Mexico.
Organism/
antimicrobials
Adult population (n=1100)
Outpatients (n=1006) Inpatients (n=94)
n % n %
S I R S I R
ESBL E. coli n (%) 700 (69.5) 68 (72.4)
Amikacin 700 41.7 49.6 8.7 68 36.7 51.5 11.8
Gentamicin 700 19.9 18.3 61.2 68 14.7 17.6 67.7
Ampicillin/
Sulbactam
700 0 0 100 68 0 0 100
Ampicillin 700 0.7 0.1 99.2 68 1.5 4.4 94.1
Amoxicilline/
Clavulanate
275 23.6 46.2 30.2 34 20.6 44.1 35.3
Ceftazidime 700 25.7 15.4 58.9 68 14.7 19.1 66.2
Cefuroxime 700 8.0 15.0 77.0 68 8.8 10.3 80.9
Ceftriaxone 700 31.6 2.3 66.1 68 25.0 2.9 72.1
Ciprofloxacin 700 13.4 0.9 85.7 68 7.4 0 92.6
Levofloxacin 700 14.7 5.4 79.9 68 10.3 2.9 86.8
Imipenem 700 99.4 0.3 0.3 68 98.5 0 1.5
Ertapenem 425 98.8 0.9 0.2 34 100 0 0
Meropenem 425 99.8 0.2 0 34 100 0 0
Piperacillin 700 0.6 0.6 98.8 68 1.5 2.9 95.6
Piperacillin/
Tazobactam
699 23.3 28.6 48.1 68 11.7 26.5 61.8
TMP/SMX 699 34.2 1.0 64.8 68 41.2 2.9 55.9
Nitrofurantoin 698 81.9 6.6 11.5 68 69.1 8.8 22.1
Non-ESBL E. coli 
n (%)
251 (25.0) 19 (20.2)
Amikacin 251 74.5 24.7 0.8 19 73.7 21.1 5.3
Organism/
antimicrobials
Adult population (n=1100)
Outpatients (n=1006) Inpatients (n=94)
n % n %
S I R S I R
Gentamicin 251 55.4 22.7 21.9 19 63.2 10.5 26.3
Ampicillin/
Sulbactam
251 0 0 100 19 0 0 100
Ampicillin 251 2.8 3.2 94.0 19 0 0 100
Amoxicillin/
Clavulanate
81 7.4 25.9 3.7 5 60.0 40.0 0
Ceftazidime 251 89.6 2.8 7.6 19 84.2 10.5 5.3
Cefuroxime 251 67.3 23.5 9.2 19 57.9 21.1 21.1
Ceftriaxone 251 91.6 2.8 5.6 19 84.2 5.3 10.5
Ciprofloxacin 251 47.4 4.8 47.8 19 52.6 0 47.4
Levofloxacin 251 51.0 17.1 31.9 19 52.6 10.5 36.8
Imipenem 251 97.2 1.2 1.6 19 94.7 0 5.3
Ertapenem 170 94.7 2.4 2.9 14 92.9 0 7.1
Meropenem 170 97.6 0 2.4 14 92.9 0 7.1
Piperacillin 251 1.2 6.0 92.8 19 0 10.5 89.5
Piperacillin/
Tazobactam
251 53.0 33.0 14.0 19 57.9 26.3 15.8
TMP/SMX 251 27.1 0 72.9 19 21.1 0 78.9
Nitrofurantoin 251 82.1 9.6 8.4 19 78.9 0 21.1
Klebsiella ozanae 
n (%)
10 (1.0) 2 (2.1)
Amikacin 10 50.0 50.0 0 2 50.0 50.0 0
Gentamicin 10 40.0 10.0 50.0 2 100.0 0 0
Ampicillin/
Sulbactam
10 0 0 100 2 0 0 100
Ampicillin 10 0 0 100 2 0 0 100
AMOX/CLAV 10 30.0 30.0 40.0 2 0 100 0
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Organism/
antimicrobials
Adult population (n=1100)
Outpatients (n=1006) Inpatients (n=94)
n % n %
S I R S I R
Ceftazidime 10 50.0 30.0 20.0 2 50.0 0 50.0
Cefuroxime 10 30.0 10.0 60.0 2 50.0 0 50.0
Ceftriaxone 10 50.0 10.0 40.0 2 50.0 0 50.0
Ciprofloxacin 10 40.0 10.0 50.0 2 0 0 100.0
Levofloxacin 10 50.0 10.0 40.0 2 0 0 100.0
Imipenem 10 100 0 0 2 100.0 0 0
Piperacillin 10 0 0 100 2 0 0 100.0
Piperacillin/
Tazobactam
10 30.0 40.0 30.0 2 0 50.0 50.0
TMP/SMX 10 20.0 10.0 70.0 2 0 50.0 50.0
Nitrofurantoin 10 20.0 40.0 40.0 2 50.0 0 50.0
Klebsiella 
pneumonie n (%)
15 (1.5) 2 (2.1)
Amikacin 15 80.0 20.0 0 2 50.0 50.0 0
Gentamicin 10 40.0 10.0 50.0 2 50.0 50.0 0
Ampicillin/
sulbactam
15 0 0 100 2 0 0 100.0
Ampicillin 15 0 0 100 2 0 0 100.0
Amoxicillin/
Clavulanate
15 20.0 46.7 33.3 2 0 0 100.0
Ceftazidime 15 60.0 13.3 26.7 2 50.0 0 50.0
Cefuroxime 15 13.3 26.7 60.0 2 0 0 100.0
Ceftriaxone 15 40.0 0 60.0 2 50.0 0 50.0
Ciprofloxacin 15 33.3 13.4 53.3 2 0 50.0 50.0
Levofloxacin 15 53.3 6.7 40.0 2 0 50.0 50.0
Imipenem 15 93.3 0 6.7 2 100.0 0 0
Organism/
antimicrobials
Adult population (n=1100)
Outpatients (n=1006) Inpatients (n=94)
n % n %
S I R S I R
Piperacillin 15 0 6.7 93.3 2 0 50.0 50.0
Piperacillin/
Tazobactam
15 20.0 40.0 40.0 2 50.0 50.0 0
TMP/SMX 15 13.3 6.7 80.0 2 0 50.0 50.0
Nitrofurantoin 15 6.7 20.0 73.3 2 0 0 100.0
Morganella 
morgani n (%)
19 (1.9) 2 (2.1)
Amikacin 19 47.4 42.1 10.5 2 0 100.0 0
Gentamicin 19 21.1 26.3 52.6 2 50.0 0 50.0
Ampicillin/
sulbactam
19 0 0 100 2 0 0 100.0
Ampicillin 19 0 0 100 2 0 0 100.0
Amoxicillin/
Clavulanate
19 0 0 100 2 0 0 100.0
Ceftazidime 19 10.5 10.5 79.0 2 0 0 100.0
Cefuroxime 19 0 0 100 2 0 0 100.0
Ceftriaxone 19 31.6 52.6 15.8 2 50.0 0 50.0
Ciprofloxacin 19 42.1 5.3 52.6 2 0 100.0 0
Levofloxacin 19 42.1 31.6 26.3 2 100.0 0 0
Imipenem 19 31.6 47.4 21.0 2 0 50.0 50.0
Piperacillin 19 5.3 5.3 89.5 2 0 0 100.0
Piperacillin/
Tazobactam
19 36.8 42.1 21.1 2 50.0 50.0 0
TMP/SMX 19 21.1 0 78.9 2 0 0 100.0
Nitrofurantoin 19 0 26.3 73.7 2 50.0 0 50.0
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Organism/
antimicrobials
Adult population (n=1100)
Outpatients (n=1006) Inpatients (n=94)
n % n %
S I R S I R
Proteus mirabilis 
n (%)
11 (1.1) 1 (1.1)
Amikacin 11 36.4 63.6 0 1 0 100.0 0
Gentamicin 11 18.2 27.3 54.5 1 0 100.0 0
Ampicillin/
sulbactam
11 0 0 100 1 0 0 100.0
Ampicillin 10 10.0 0 90.0 1 0 0 100.0
Amoxicillin/
Clavulanate
11 18.2 0 81.8 1 0 0 100.0
Ceftazidime 11 18.2 36.4 45.4 1 0 0 100.0
Cefuroxime 11 27.3 27.3 45.4 1 0 0 100.0
Ceftriaxone 11 81.8 9.1 9.1 1 0 100.0 0
Levofloxacin 11 45.4 18.2 36.4 1 100.0 0 0
Imipenem 11 36.4 9.1 54.5 1 100.0 0 0
Piperacillin 11 0 0 100 1 0 0 100.0
Piperacillin/
Taxobactam
11 45.4 36.4 18.2 1 0 100.0 0
TMP/SMX 11 9.1 9.1 81.8 1 0 0 100.0
Nitrofurantoin 11 0 18.2 81.2 1 0 0 100.0
Sensible (S), Intermediate (I), Resistant (R), Trympetroprim sulfametoxazol (TMP/SMX)
Table 5.  Antimicrobial activity against Gram-negative organisms collected 
from urine samples in children from Jalisco (2012-2013).
Organism/
antimicrobials
Pediatric population (n=106)
Outpatients (n=90) Inpatients (n=16)
n % n %
S I R S I R
ESBL E. coli n (%) 48 (53.3) 8 (50.0)
Amikacin 48 85.4 10.4 4.2 8 50.0 37.5 12.5
Gentamicin 48 25.0 18.8 56.2 8 12.5 12.5 75.0
Ampicillin/
sulbactam
48 0 0 100.0 8 0 0 100.0
Ampicillin 48 0 2.1 97.9 8 0 0 100.0
Amoxicillin/
Clavulanate
48 31.3 0 68.7 8 37.5 25.0 37.5
Ceftazidime 48 47.9 8.3 43.8 8 25.0 12.5 62.5
Cefuroxime 48 27.1 8.3 64.6 8 12.5 25.0 62.5
Ceftriaxone 48 43.8 2.1 54.2 8 50.0 12.5 37.5
Ciprofloxacin 48 39.6 0 60.4 8 50.0 0 50.0
Levofloxacin 48 41.7 4.2 54.2 8 50.0 0 50.0
Imipenem 48 100.0 0 0 8 87.5 0 12.5
Ertapenem 2 100.0 0 0 0 - - -
Meropenem 2 100.0 0 0 0 - - -
Piperacillin 48 0 6.3 93.7 8 0 0 100.0
Piperacillin/
Tazobactam
48 43.8 22.9 33.3 8 25.0 25.0 50.0
TMP/SMX 48 25.0 2.1 72.9 8 37.5 0 62.5
Nitrofurantoin 48 85.4 2.1 12.5 8 87.5 0 12.5
Non-ESBL E. coli 
n(%)
33 (36.7) 4 (25.0)
Amikacin 33 97.0 3.0 0 4 75.0 25.0 0
Gentamicin 33 39.4 54.5 6.1 4 0 100.0 0
InternatIonal archIves of MedIcIne
Section: Microbiology 
Issn: 1755-7682 
2015
Vol. 8 No. 148
doi: 10.3823/1747
This article is available at: www.intarchmed.com and www.medbrary.com 12
Organism/
antimicrobials
Pediatric population (n=106)
Outpatients (n=90) Inpatients (n=16)
n % n %
S I R S I R
Ampicillin/
sulbactam
33 0 0 100.0 4 0 0 100.0
Ampicillin 33 3.0 0 97.0 4 0 0 100.0
Amoxicillin/
Clavulanate
32 43.8 0 56.2 4 50.0 0 50.0
Ceftazidime 33 100.0 0 0 4 100.0 0 0
Cefuroxime 33 94.0 3.0 3.0 4 100.0 0 0
Ceftriaxone 33 100.0 0 0 4 100.0 0 0
Ciprofloxacin 33 84.8 0 15.2 4 75.0 0 25.0
Levofloxacin 33 84.9 3.0 12.1 4 75.0 25.0 0
Imipenem 33 100.0 0 0 4 100.0 0 0
Ertapenem 1 100.0 0 0 0 - - -
Meropenem 1 100.0 0 0 0 - - -
Piperacillin 33 0 0 100.0 4 0 0 100.0
Piperacillin/
Tazobactam
33 69.7 24.2 6.1 4 75.0 25.0 0
TMP/SMX 33 9.1 0 90.9 4 0 0 100.0
Nitrofurantoin 33 93.9 0 6.1 4 100.0 0 0
Klebsiella ozanae 
n(%)
1 (1.1) 2 (12.4)
Amikacin 1 100.0 0 0 2 100.0 0 0
Gentamicin 1 0 100.0 0 2 50.0 50.0 0
Ampicillin/
sulbactam
1 0 0 100.0 2 0 0 100.0
Ampicillin 1 0 0 100.0 2 0 0 100.0
Amoxicillin/
Clavulanate
1 100.0 0 0 2 50.0 0 50.0
Organism/
antimicrobials
Pediatric population (n=106)
Outpatients (n=90) Inpatients (n=16)
n % n %
S I R S I R
Ceftazidime 1 100.0 0 0 2 100.0 0 0
Cefuroxime 1 100.0 0 0 2 50.0 0 50.0
Ceftriaxone 1 100.0 0 0 2 100.0 0 0
Ciprofloxacin 1 100.0 0 0 2 100.0 0 0
Levofloxacin 1 100.0 0 0 2 100.0 0 0
Imipenem 1 100.0 0 0 2 100.0 0 0
Piperacillin 1 0 0 100.0 2 0 0 100.0
Piperacillin/
Tazobactam
1 100.0 0 0 2 100.0 0 0
TMP/SMX 1 0 0 100.0 2 50.0 0 50.0
Nitrofurantoin 1 100.0 0 0 2 50.0 0 50.0
Klebsiella 
pneumonie n(%)
1 (1.1) 0 (0)
Amikacin 1 100.0 0 0 0 - - -
Getamicin 1 0 0 100.0 0 - - -
Ampicillin/
sulbactam
1 0 0 100.0 0 - - -
Ampicillin 1 0 0 100.0 0 - - -
Amoxicillin/
Clavulanate
1 0 0 100.0 0 - - -
Ceftazidime 1 0 0 100.0 0 - - -
Cefuroxime 1 0 0 100.0 0 - - -
Ceftriaxone 1 0 0 100.0 0 - - -
Ciprofloxacin 1 0 0 100.0 0 - - -
Levofloxacin 1 100.0 0 0 0 - - -
Imipenem 1 100.0 0 0 0 - - -
Piperacillin 1 0 0 100.0 0 - - -
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Organism/
antimicrobials
Pediatric population (n=106)
Outpatients (n=90) Inpatients (n=16)
n % n %
S I R S I R
Piperacillin/
Tazobactam
1 100.0 0 0 0 - - -
TMP/SMX 1 0 0 100.0 0 - - -
Nitrofurantoin 1 0 100.0 0 0 - - -
Morganella 
morgani n(%)
2 (2.2) 1 (6.3)
Amikacin 2 50.0 50.0 0 1 0 100.0 0
Gentamicin 2 50.0 50.0 0 1 0 100.0 0
Ampicillin/
sulbactam
2 0 0 100.0 1 0 0 100.0
Ampicillin 2 0 0 100.0 1 0 0 100.0
Amoxicillin/
Clavulanate
2 0 0 100.0 1 0 100.0 0
Ceftazidime 2 0 0 100.0 1 0 0 100.0
Cefuroxime 2 0 0 100.0 1 0 0 100.0
Ceftriaxone 2 50.0 50.0 0 1 0 100.0 0
Ciprofloxacin 2 100.0 0 0 1 100.0 0 0
Levofloxacin 2 100.0 0 0 1 100.0 0 0
Imipenem 2 0 0 100.0 1 0 0 100.0
Piperacillin 2 0 0 100.0 1 0 0 100.0
Piperacillin/
Tazobactam
2 50.0 50.0 0 1 0 100.0 0
TMP/SMX 2 50.0 0 50.0 1 100.0 0 0
Nitrofurantoin 2 0 0 100.0 1 0 0 100.0
Organism/
antimicrobials
Pediatric population (n=106)
Outpatients (n=90) Inpatients (n=16)
n % n %
S I R S I R
Proteus mirabilis 
n (%)
5 (5.6) 1 (6.3)
Amikacin 5 80.0 20.0 0 1 100.0 0 0
Gentamicin 5 20.0 60.0 20.0 1 0 100.0 0
Ampicillin/
sulbactam
5 0 0 100.0 1 0 0 100.0
Ampicillin 5 0 0 100.0 1 0 0 100.0
Amoxicillin/
Clavulanate
5 0 0 100.0 1 0 100.0 0
Ceftazidime 5 0 40.0 60.0 1 0 0 100.0
Cefuroxime 5 0 0 100.0 1 0 100.0 0
Ceftriaxone 5 40.0 40.0 20.0 1 100.0 0 0
Ciprofloxacin 5 60.0 0 40.0 1 100.0 0 0
Levofloxacin 5 80.0 20.0 0 1 100.0 0 0
Imipenem 5 80.0 0 20.0 1 0 0 100.0
Piperacillin 5 40.0 0 60.0 1 0 0 100.0
Piperacillin/
Tazobactam
5 60.0 0 40.0 1 0 0 100.0
TMP/SMX 5 0 0 100.0 1 100.0 0 0
Sensible (S), Intermediate (I), Resistant (R), Trympetroprim sulfametoxazole (TMP/SMX). 
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cing E. coli have been increasingly reported [2, 
27]. Over the last two decades, the proportion of 
community-acquired ESBL-producing E. coli strains 
with resistance to first-line antimicrobial agents, 
such as ampicillin, cephalosporins, TMP-SMX, and 
fluoroquinolones have increased globally, further 
complicating the management of UTI infections 
[2]. While β-lactamases may be chromosomally 
encoded and universally present in a species or 
plasmid mediated, the main type of commonly 
found ESBL in Klebsiella and Escherichia coli are 
SHV-1 and SHV-2 enzymes (for sulphydral varia-
ble type 1). The second largest group of ESBLs 
are CTX-M enzymes. Indeed E. coli that produce 
CTX-M enzymes have been identified as a cau-
se of UTIs, mainly in the community setting [29]. 
Various reports suggest that CTX-M-type ESBLs 
may now be the most frequently encountered 
ESBL worldwide [30].
Currently, in order to establish diagnosis, a pre-
sence of 1,000 to 10,000 colony-forming units 
(CFU)/mL is required [4]. Accordingly, physicians 
are encouraged to avoid prescribing antibiotics 
to patients with low-colony-count urine speci-
mens, in order to decrease unnecessary exposure 
to antibiotics that may lead to the development 
of multidrug-resistant bacteria and other negative 
antibiotic-related conditions and side effects [4]. 
Furthermore, fluoroquinolones are no longer the 
first line of treatment in cases of uncomplicated 
cystitis or pyelonephritis, according to both the 
Infectious Diseases Society of America (IDSA) and 
the medical guidelines published by the European 
Society for Microbiology and Infectious Diseases 
(ESCMID) [31]. 
The knowledge of specific risk factors for re-
sistance development should help guide the se-
lection of the appropriate antibiotic treatment 
and assist in the designing of appropriate control 
programs to reduce morbidity and costs related 
to UTIs worldwide, emphasizing the need to per-
form urine cultures before initiating antimicrobial 
treatment. This report will ideally encourage a 
more scientific and measured use of antibiotics 
which is of utmost importance, not only for pa-
tients who live in Mexico and Latin America, but 
also for travelers whom have acquired infections 
during their visits to these countries. 
Our study has several potential limitations; the 
lack of data on clinical information, including pre-
vious antimicrobial treatments and recurrence of 
infection rates, due to study design, may result in 
information bias, although it is unlikely that this 
would result in differential bias. Furthermore, the 
antibiotic fosfomycin was not analyzed herein ba-
sed on urine culture susceptibility tests that gene-
rally indicate low resistance rates for this drug. A 
follow-up study, incorporating additional informa-
tion via informed consent permission, would be 
useful to establish associations between risk fac-
tors and resistance rates to specific antimicrobials. 
Such findings may, in turn, elucidate an alternative 
treatment option for uncomplicated cystitis cau-
sed by ESBL-producing E. coli infection, to mini-
mize the current indicated use of carbapenems, 
which may better be reserved for more severe 
infections, in order to preserve its low resistance 
profile. 
Conclusion
Data analyzed in this review is relevant to Mexico, 
Latin America and patients worldwide who have 
contracted UTIs while traveling to Mexico and other 
parts of Latin America, before returning to their 
home country. Additionally this study supports the 
need for improved education of health care workers 
regarding the use of antimicrobials as part of an 
international antibiotic stewardship program. Taken 
together, these suggested changes may not only 
benefit patients with UTIs, but may also go a long 
way to reduce the presence of antimicrobial agent 
resistant bacteria generally.
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